UBS Group Increases IDEXX Laboratories (NASDAQ:IDXX) Price Target to $670.00

IDEXX Laboratories (NASDAQ:IDXX) had its price objective lifted by analysts at UBS Group from $620.00 to $670.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s price target would suggest a potential upside of 14.57% from the company’s previous close.

IDXX has been the subject of a number of other research reports. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $756.00.

IDEXX Laboratories Trading Down 0.6%

IDXX stock traded down $3.31 during trading on Wednesday, reaching $584.78. 908,538 shares of the stock traded hands, compared to its average volume of 586,405. The business’s 50 day moving average price is $558.15 and its 200-day moving average price is $587.56. The firm has a market capitalization of $46.13 billion, a PE ratio of 43.06, a P/E/G ratio of 3.11 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories has a 52-week low of $518.55 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories will post 14.68 earnings per share for the current year.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Elyxium Wealth LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $3,666,459,000. State Street Corp increased its position in shares of IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after purchasing an additional 138,956 shares during the period. J. Stern & Co. LLP raised its stake in shares of IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC increased its holdings in IDEXX Laboratories by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares during the period. Finally, Invesco Ltd. boosted its position in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after acquiring an additional 181,955 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Second-quarter results exceeded expectations. IDEXX reported adjusted earnings of $4.27 per share versus consensus estimates of approximately $3.94-$3.95, while revenue reached $1.217 billion, ahead of the $1.20 billion forecast. Revenue increased 10% year over year, or 9% organically. IDEXX Laboratories Announces Second Quarter Results
• Positive Sentiment: Growth was broad-based. Companion Animal Group revenue rose 9% organically, Water revenue grew 13% organically, and Livestock, Poultry and Dairy revenue increased 9% organically, supporting the view that demand for veterinary diagnostics remains healthy. IDXX Q2 Earnings and Revenues Beat, 2026 EPS View Up
• Positive Sentiment: Full-year EPS guidance was raised. IDEXX now expects 2026 earnings of $14.69-$14.94 per share, above the $14.64 analyst consensus. Management also highlighted margin expansion, continued diagnostic adoption and strong recurring business trends. IDEXX Laboratories Jumps on Strong Results and Raised Guidance
• Neutral Sentiment: Investors may be taking profits after the initial earnings rally. With shares valued at roughly 43 times earnings and trading near the 200-day average, the strong report may already be partly reflected in the price. The company’s revenue outlook of approximately $4.7 billion was broadly in line with consensus, offering limited additional upside on that measure. IDEXX Laboratories Earnings Call Highlights Strong Growth

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.